← All trials
NCT06973187
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 4, 2025
- Primary completion
- Apr 17, 2028
- Completion date
- Apr 17, 2028
- First posted
- May 15, 2025
- Last posted
- Nov 21, 2025
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BeOne MedicinesLead sponsor
- BeOne MedicinesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.